Endocrine therapy for hormone treatment-naïve advanced breast cancer.
A proportion of patients with hormone receptor-positive locally advanced or metastatic breast cancer will not have received prior endocrine therapy. However, there are limited clinical data specifically in these patients. We conducted a review of randomized phase II and III clinical studies of anastrozole, letrozole, exemestane, palbociclib, and fulvestrant to determine the evidence base supporting use of specific endocrine therapies in this patient population. From our findings, there is a paucity of clinical studies in patients with endocrine therapy-naïve disease; however, it appears that first-line treatment effects are consistent between patients who have and have not received prior endocrine treatment.
Medical Oncology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, C/Dr Esquerdo 46, Madrid 28009, Spain. Electronic address: mmartin@geicam.org.
Miguel
M
Martin
Medical Oncology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, C/Dr Esquerdo 46, Madrid 28009, Spain. Electronic address: slopeztarruella@gmail.com.
Sara
S
Lopez-Tarruella
Medical Oncology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, C/Dr Esquerdo 46, Madrid 28009, Spain. Electronic address: itacayoli@hotmail.com.
Yolanda Jerez
YJ
Gilarranz
D000077384:Anastrozole; D000730:Androstadienes / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D010879:Piperazines; D011725:Pyridines; D014230:Triazoles; D013629:Tamoxifen; D000077267:Fulvestrant; D000068258:Bevacizumab; D000077384:Anastrozole; D004958:Estradiol; D000077289:Letrozole; C500026:palbociclib; C056516:exemestane
Advanced breast cancer; Endocrine therapy; Endocrine therapy-naïve; Metastatic breast cancer